Log in to search using one of your social media accounts:

 

Novel molecular classifications of DLBCL
Novel molecular classifications of DLBCL, Published online: 22 May 2018; doi:10.1038/s41571-018-0041-zRecent genomic and transcriptomic analyses of diffuse large B cell lymphoma (DLBCL) have provided important new insights into the heterogeneous biology of this disease. The findings provide opportunities to improve treatment strategies, although considerable work is needed to establish and optimize the clinical applicability and utility of molecular classifications of DLBCL. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 22, 2018 Category: Cancer & Oncology Authors: Sydney Dubois Fabrice Jardin Source Type: research

Neoadjuvant FOLFIRINOX improves outcomes
Neoadjuvant FOLFIRINOX improves outcomes, Published online: 22 May 2018; doi:10.1038/s41571-018-0043-xNeoadjuvant FOLFIRINOX improves outcomes (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 22, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Genomics reveals distinct gastric cancer subtypes
Genomics reveals distinct gastric cancer subtypes, Published online: 22 May 2018; doi:10.1038/s41571-018-0044-9Genomics reveals distinct gastric cancer subtypes (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 22, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

CTCs and benefit from radiotherapy
CTCs and benefit from radiotherapy, Published online: 21 May 2018; doi:10.1038/s41571-018-0042-yCTCs and benefit from radiotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 21, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Clinical utility of circulating non-coding RNAs — an update
Clinical utility of circulating non-coding RNAs — an updateClinical utility of circulating non-coding RNAs — an update, Published online: 21 May 2018; doi:10.1038/s41571-018-0035-xEvidence of the functional roles of non-coding RNAs in cancer is expanding, and the potential of these RNAs as diagnostic and prognostic biomarkers is increasingly recognized. Herein, the authors review the recent developments in these areas and provide compendiums of circulating microRNAs and long non-coding RNAs that have promise as diagnostic and prognostic cancer biomarkers. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 21, 2018 Category: Cancer & Oncology Authors: Simone Anfossi Anna Babayan Klaus Pantel George A. Calin Source Type: research

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapyEvolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy, Published online: 18 May 2018; doi:10.1038/s41571-018-0037-8In recent years, a number of novel agents have been added to the therapeutic armamentarium for patients with chronic lymphocytic leukaemia (CLL). Herein, Jan A. Burger and Susan O’Brien outline the emerging paradigm of individualized therapy for patients with CLL aimed at exploiting the advantages of these novel agents but also integrating traditional therapies for ...
Source: Nature Clinical Practice Oncology - May 18, 2018 Category: Cancer & Oncology Authors: Jan A. Burger Susan O ’Brien Source Type: research

Only the best CAR T cells
Only the best CAR T cells, Published online: 14 May 2018; doi:10.1038/s41571-018-0039-6Only the best CAR T cells (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 14, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Low-value approvals and high prices might incentivize ineffective drug development
Low-value approvals and high prices might incentivize ineffective drug development, Published online: 14 May 2018; doi:10.1038/s41571-018-0030-2Drug regulators’ acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 14, 2018 Category: Cancer & Oncology Authors: Vinay Prasad Christopher McCabe Sham Mailankody Source Type: research

Poziotinib for uncommon ERBB mutations
Poziotinib for uncommon ERBB mutations, Published online: 09 May 2018; doi:10.1038/s41571-018-0038-7Poziotinib for uncommon ERBB mutations (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 9, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Sustainability and affordability of cancer drugs: a novel pricing model
Sustainability and affordability of cancer drugs: a novel pricing model, Published online: 07 May 2018; doi:10.1038/s41571-018-0027-xThe affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 7, 2018 Category: Cancer & Oncology Authors: Carin A. Uyl-de Groot Bob L öwenberg Source Type: research

Pembrolizumab synergizes with chemotherapy
Pembrolizumab synergizes with chemotherapy, Published online: 03 May 2018; doi:10.1038/s41571-018-0031-1Pembrolizumab synergizes with chemotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Treatment resistance in urothelial carcinoma: an evolutionary perspective
Treatment resistance in urothelial carcinoma: an evolutionary perspective, Published online: 02 May 2018; doi:10.1038/s41571-018-0026-yPatients with advanced-stage urothelial carcinoma typically receive chemotherapy and might also receive immune-checkpoint inhibitorsfollowing disease progression. However, the majority of patients will ultimately develop resistance to treatment. In this Review, the authors describe the evolutionary mechanisms of treatment resistance in patients with urothelial carcinoma. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 2, 2018 Category: Cancer & Oncology Authors: Panagiotis J. Vlachostergios Bishoy M. Faltas Source Type: research

Author Correction: Analysis of DNA methylation in cancer: location revisited
Author Correction: Analysis of DNA methylation in cancer: location revisited, Published online: 30 April 2018; doi:10.1038/s41571-018-0028-9Author Correction: Analysis of DNA methylation in cancer: location revisited (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 30, 2018 Category: Cancer & Oncology Authors: Alexander Koch Sophie C. Joosten Zheng Feng Tim C. de Ruijter Muriel X. Draht Veerle Melotte Kim M. Smits Jurgen Veeck James G. Herman Leander Van Neste Wim Van Criekinge Tim de Meyer Manon van Engeland Source Type: research

Nivolumab–ipilimumab — exploiting the mutation burden of NSCLCs
Nivolumab–ipilimumab — exploiting the mutation burden of NSCLCsNivolumab–ipilimumab — exploiting the mutation burden of NSCLCs, Published online: 27 April 2018; doi:10.1038/s41571-018-0034-yNivolumab–ipilimumab — exploiting the mutation burden of NSCLCs (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 27, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Neoadjuvant PD-1 blockade in NSCLC
Neoadjuvant PD-1 blockade in NSCLC, Published online: 26 April 2018; doi:10.1038/s41571-018-0032-0Neoadjuvant PD-1 blockade in NSCLC (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 26, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Tracing the steps of cancer evolution
Tracing the steps of cancer evolution, Published online: 26 April 2018; doi:10.1038/s41571-018-0033-zTracing the steps of cancer evolution (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Conor A. Bradley Source Type: research

How to eliminate gastric cancer-related death worldwide?
How to eliminate gastric cancer-related death worldwide?, Published online: 26 April 2018; doi:10.1038/s41571-018-0029-8Helicobacter pylori eradication therapy is effective in preventing gastric cancer, even in patients with advanced pre-neoplastic lesions (gastric atrophy and/or intestinal metaplasia). We must now focus on how to accomplish the goal of eliminating gastric cancer-related death worldwide; strategies for screening and treatment of gastric neoplasia (primary prevention) and post-treatment surveillance (secondary prevention) are discussed herein. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Yoshio Yamaoka Source Type: research

Does nonmetastatic castration-resistant prostate cancer still exist?
Does nonmetastatic castration-resistant prostate cancer still exist?, Published online: 23 April 2018; doi:10.1038/s41571-018-0025-zAfter almost 20 years of negative trials of novel therapies for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), two androgen receptor antagonists have shown favourable outcomes in phase III trials involving patients with high-risk nmCRPC. Herein, the history of nmCRPC and clinical trials in this disease setting are discussed and a perspective on molecular imaging and clinical management of nmCRPC is offered. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 23, 2018 Category: Cancer & Oncology Authors: Celestia S. Higano Source Type: research

The multiple myelomas — current concepts in cytogenetic classification and therapy
The multiple myelomas — current concepts in cytogenetic classification and therapyThe multiple myelomas — current concepts in cytogenetic classification and therapy, Published online: 23 April 2018; doi:10.1038/s41571-018-0018-yThe multiple myelomas (MMs) are heterogeneous malignancies that are nearly always associated with chromosomal abnormalities, which can be considered either primary or secondary abnormalities. The classification of MM according to the underlying primary cytogenetic abnormality might enable the development of better treatment strategies. The authors describe treatment approaches that consi...
Source: Nature Clinical Practice Oncology - April 23, 2018 Category: Cancer & Oncology Authors: Shaji K. Kumar S. Vincent Rajkumar Source Type: research

The paradox of precision medicine
We describe how approaches to precision medicine can lead, paradoxically, to increased levels of uncertainty. We offer recommendations for how physicians can better navigate new uncertainties in precision medicine. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 19, 2018 Category: Cancer & Oncology Authors: Jonathan Kimmelman Ian Tannock Source Type: research

Nivolumab effective in treatment-resistant HL
Nivolumab effective in treatment-resistant HL, Published online: 18 April 2018; doi:10.1038/s41571-018-0022-2Nivolumab effective in treatment-resistant HL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 18, 2018 Category: Cancer & Oncology Source Type: research

Crizotinib active in patients of East Asian ethnicity
Crizotinib active in patients of East Asian ethnicity, Published online: 18 April 2018; doi:10.1038/s41571-018-0024-0Crizotinib active in patients of East Asian ethnicity (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 18, 2018 Category: Cancer & Oncology Source Type: research

Combination effective against brain metastases
Combination effective against brain metastases, Published online: 18 April 2018; doi:10.1038/s41571-018-0023-1Combination effective against brain metastases (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 18, 2018 Category: Cancer & Oncology Source Type: research

CheckMate 214 — a winning combination?
CheckMate 214 — a winning combination?CheckMate 214 — a winning combination?, Published online: 17 April 2018; doi:10.1038/s41571-018-0020-4CheckMate 214 — a winning combination? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours
Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours, Published online: 17 April 2018; doi:10.1038/s41571-018-0012-4Patients with sarcomas have historically been treated with surgery and/or chemotherapy, although the outcomes achieved with these approaches, especially in advanced-stage disease, are often disappointing. In this Review, the authors describe the opportunities created by selective use of targeted therapies on the basis of the biological characteristics of individual tumours. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Armelle Dufresne Mehdi Brahmi Marie Karanian Jean-Yves Blay Source Type: research

Analysis of DNA methylation in cancer: location revisited
Analysis of DNA methylation in cancer: location revisited, Published online: 17 April 2018; doi:10.1038/s41571-018-0004-4Despite extensive research efforts, very few DNA methylation-based biomarkers have been implemented clinically. In this Perspective, the authors describe the importance of considering the genomic locations examined in determining the diagnostic or prognostic relevance of putative DNA methylation-based biomarkers. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Alexander Koch Sophie C. Joosten Zheng Feng Tim C. de Ruijter Muriel X. Draht Veerle Melotte Kim M. Smits Jurgen Veeck James G. Herman Leander Van Neste Wim Van Criekinge Tim De Meyer Manon van Engeland Source Type: research

New subtypes of high-grade neuroendocrine tumours revealed
New subtypes of high-grade neuroendocrine tumours revealed, Published online: 16 April 2018; doi:10.1038/s41571-018-0015-1New subtypes of high-grade neuroendocrine tumours revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Targeted combination has synergy in MCL
Targeted combination has synergy in MCL, Published online: 16 April 2018; doi:10.1038/s41571-018-0021-3Targeted combination has synergy in MCL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Postoperative chemoradiotherapy versus radiotherapy for high-risk cutaneous disease
Postoperative chemoradiotherapy versus radiotherapy for high-risk cutaneous disease, Published online: 16 April 2018; doi:10.1038/s41571-018-0014-2Postoperative chemoradiotherapy versus radiotherapy for high-risk cutaneous disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Venetoclax–rituximab holds substantial promise in CLL
Venetoclax–rituximab holds substantial promise in CLLVenetoclax–rituximab holds substantial promise in CLL, Published online: 12 April 2018; doi:10.1038/s41571-018-0017-zVenetoclax–rituximab holds substantial promise in CLL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 12, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Encorafenib — a new agent for advanced-stage disease
Encorafenib — a new agent for advanced-stage diseaseEncorafenib — a new agent for advanced-stage disease, Published online: 12 April 2018; doi:10.1038/s41571-018-0019-xEncorafenib — a new agent for advanced-stage disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 12, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Targeting the tumour stroma to improve cancer therapy
Targeting the tumour stroma to improve cancer therapy, Published online: 12 April 2018; doi:10.1038/s41571-018-0007-1The tumour stroma is a component of the tumour microenvironment and has crucial roles in tumour initiation, progression, and metastasis. Most anticancer therapies target cancer cells specifically, but the tumour stroma can promote resistance to such therapies. Herein, the authors provide an overview of the complex cancer cell–tumour stroma interactions and discuss how novel treatment strategies should combine anticancer and antistromal agents. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 12, 2018 Category: Cancer & Oncology Authors: Kenneth C. Valkenburg Amber E. de Groot Kenneth J. Pienta Source Type: research

MRI improves diagnosis
MRI improves diagnosis, Published online: 11 April 2018; doi:10.1038/s41571-018-0013-3MRI improves diagnosis (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 11, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Current state of immunotherapy for glioblastoma
Current state of immunotherapy for glioblastoma, Published online: 11 April 2018; doi:10.1038/s41571-018-0003-5Glioblastoma is a disease associated with a dismal patient prognosis, necessitating the development of novel therapies. Substantial research effort is being devoted to the development of immunotherapies for glioblastoma. Herein, the rationale and promise for this approach are discussed, together with the challenges and how they might be overcome. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 11, 2018 Category: Cancer & Oncology Authors: Michael Lim Yuanxuan Xia Chetan Bettegowda Michael Weller Source Type: research

The gut microbiota influences anticancer immunosurveillance and general health
The gut microbiota influences anticancer immunosurveillance and general health, Published online: 10 April 2018; doi:10.1038/s41571-018-0006-2Emerging evidence indicates that the composition of the intestinal microbiota influences anticancer immunosurveillance and therefore the effectiveness of anticancer therapies, especially immune-checkpoint inhibitors. Herein, key contributors to this field of research discuss these connections between gut bacteria, anticancer immunity, and general health, with a focus on specific bacterial species consistently associated with favourable clinical outcomes of anticancer immunotherapy, a...
Source: Nature Clinical Practice Oncology - April 10, 2018 Category: Cancer & Oncology Authors: Bertrand Routy Vancheswaran Gopalakrishnan Romain Daill ère Laurence Zitvogel Jennifer A. Wargo Guido Kroemer Source Type: research

Obesity associated with resistance to anti-angiogenic therapy
Obesity associated with resistance to anti-angiogenic therapy, Published online: 06 April 2018; doi:10.1038/s41571-018-0011-5Obesity associated with resistance to anti-angiogenic therapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Improved pain management
Improved pain management , Published online: 06 April 2018; doi:10.1038/s41571-018-0010-6 Improved pain management (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Precision oncology in non-small-cell lung cancer: opportunities and challenges
Precision oncology in non-small-cell lung cancer: opportunities and challenges, Published online: 29 March 2018; doi:10.1038/s41571-018-0008-0Major advances in our understanding of the molecular pathogenesis of non-small-cell lung cancer (NSCLC) have led to effective targeted therapeutics in several genomically-defined subsets of NSCLC. The recently updated College of American Pathologists, International Association for the Study of Lung cancer, and Association for Molecular Pathology joint guideline, which was endorsed by ASCO, sets new standards for molecular testing in NSCLC. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Chul Kim Giuseppe Giaccone Source Type: research

The emerging clinical relevance of genomics in cancer medicine
The emerging clinical relevance of genomics in cancer medicine, Published online: 29 March 2018; doi:10.1038/s41571-018-0002-6Developments in genomic sequencing technologies have enabled increasing amounts of information on the genomes of individual cancers to be revealed. At the same time, increasing numbers of therapies targeting specific genomic alterations are being made available, necessitating the use of genomics to diagnose and treat patients with cancer. In this Review, the authors describe the emerging clinical relevance of genomics in oncology, in addition to the many challenges that currently preclude routine cl...
Source: Nature Clinical Practice Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Michael F. Berger Elaine R. Mardis Source Type: research

DDR signature to predict response to ICI
DDR signature to predict response to ICI, Published online: 28 March 2018; doi:10.1038/s41571-018-0005-3DDR signature to predict response to ICI (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 28, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

PET imaging reveals EGFR mutation status
PET imaging reveals EGFR mutation status, Published online: 28 March 2018; doi:10.1038/s41571-018-0009-zPET imaging reveals EGFR mutation status (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 28, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Breast cancer: Changes in clonal dynamics predict response to palbociclib
Breast cancer: Changes in clonal dynamics predict response to palbociclib, Published online: 20 March 2018; doi:10.1038/nrclinonc.2018.42Breast cancer: Changes in clonal dynamics predict response to palbociclib (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Paediatric cancer: Pan-cancer genomic analyses uncover molecular drivers
Paediatric cancer: Pan-cancer genomic analyses uncover molecular drivers, Published online: 20 March 2018; doi:10.1038/nrclinonc.2018.43Paediatric cancer: Pan-cancer genomic analyses uncover molecular drivers (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 20, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Triple-negative breast cancers — a panoply of cancer types
Triple-negative breast cancers — a panoply of cancer typesTriple-negative breast cancers — a panoply of cancer types, Published online: 19 March 2018; doi:10.1038/s41571-018-0001-7The biological complexity of triple-negative breast cancers (TNBCs) and the lack of highly recurrent targetable genetic alterations pose major challenges for the implementation of targeted therapies for this disease. A recent multiomic in silico study has identified genetic drivers of five different TNBC molecular subtypes, providing new opportunities for precision medicine approaches. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 19, 2018 Category: Cancer & Oncology Authors: Fresia Pareja Jorge S. Reis-Filho Source Type: research

A call for pragmatism in cancer research
A call for pragmatism in cancer research, Published online: 19 March 2018; doi:10.1038/nrclinonc.2018.41A call for pragmatism in cancer research (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 19, 2018 Category: Cancer & Oncology Source Type: research

Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers
Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.40Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 13, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Immunotherapy: Immune-modified response criteria — an iterative learning process?
Immunotherapy: Immune-modified response criteria — an iterative learning process?Immunotherapy: Immune-modified response criteria — an iterative learning process?, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.36Patients with solid tumours can have unusual patterns of response to anticancer immunotherapy, necessitating the adaptation of traditional response criteria. A recent retrospective analysis of data from patients with four different types of solid tumours treated with the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezolizumab confirms the previous experience in patients with me...
Source: Nature Clinical Practice Oncology - March 13, 2018 Category: Cancer & Oncology Authors: Patrick A. Ott Source Type: research

Melanoma: Time for adjuvant vemurafenib?
Melanoma: Time for adjuvant vemurafenib?, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.39Melanoma: Time for adjuvant vemurafenib? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 13, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Sarcoma: Local hyperthermia improves survival
Sarcoma: Local hyperthermia improves survival, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.38Sarcoma: Local hyperthermia improves survival (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Targeting the PI3K pathway in cancer: are we making headway?
Targeting the PI3K pathway in cancer: are we making headway?, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.28The PI3K–AKT–mTOR pathway has key roles in tumorigenesis and is dysregulated in most cancers. Consequently, numerous drugs that target key nodes of this pathway have been developed, although few of these agents have been approved for the treatment of cancer. Herein, the authors review the current experience with anticancer therapies that target the PI3K–AKT–mTOR pathway, discuss the challenges that have limited the clinical translation of these agents, and provide perspectives ...
Source: Nature Clinical Practice Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Filip Janku Timothy A. Yap Funda Meric-Bernstam Source Type: research